{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,22]],"date-time":"2026-10-22T03:02:17Z","timestamp":1792638137585,"version":"4.5.0"},"reference-count":43,"publisher":"Springer Science and Business Media LLC","issue":"10","license":[{"start":{"date-parts":[[2025,9,9]],"date-time":"2025-09-09T00:00:00Z","timestamp":1757376000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2025,9,9]],"date-time":"2025-09-09T00:00:00Z","timestamp":1757376000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Br J Cancer"],"published-print":{"date-parts":[[2025,11,30]]},"DOI":"10.1038\/s41416-025-03149-4","type":"journal-article","created":{"date-parts":[[2025,9,9]],"date-time":"2025-09-09T03:45:11Z","timestamp":1757389511000},"page":"1441-1453","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["SLC7A11-AS1 contributes to prolonged activation of activin A\/Smad signaling by suppressing PPM1A myristoylation in pancreatic cancer"],"prefix":"10.1038","volume":"133","author":[{"ORCID":"https:\/\/orcid.org\/0009-0005-0386-6955","authenticated-orcid":false,"given":"Mengmeng","family":"Li","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhicheng","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qingzhu","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fei","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xuemei","family":"Huang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Huan","family":"Nie","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kai","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8320-2182","authenticated-orcid":false,"given":"Huanjie","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,9,9]]},"reference":[{"key":"3149_CR1","first-page":"12","volume":"74","author":"RL Siegel","year":"2024","unstructured":"Siegel RL, Giaquinto AN, Jemal A. Cancer statistics, 2024. CA Cancer J Clin. 2024;74:12\u201349.","journal-title":"CA Cancer J Clin"},{"key":"3149_CR2","first-page":"1722","volume":"9","author":"C Yang","year":"2019","unstructured":"Yang C, Zhu S, Yang H, Deng S, Fan P, Li M, et al. USP44 suppresses pancreatic cancer progression and overcomes gemcitabine resistance by deubiquitinating FBP1. Am J Cancer Res. 2019;9:1722.","journal-title":"Am J Cancer Res"},{"key":"3149_CR3","doi-asserted-by":"crossref","first-page":"4755","DOI":"10.1002\/cam4.1729","volume":"7","author":"KH Chen","year":"2018","unstructured":"Chen KH, Guo Y, Li L, Qu S, Zhao W, Lu QT, et al. Cancer stem cell\u2010like characteristics and telomerase activity of the nasopharyngeal carcinoma radioresistant cell line CNE\u20102R. Cancer Med. 2018;7:4755.","journal-title":"Cancer Med"},{"key":"3149_CR4","doi-asserted-by":"crossref","DOI":"10.1038\/s41467-020-16395-2","volume":"11","author":"S Alcal\u00e1","year":"2020","unstructured":"Alcal\u00e1 S, Sancho P, Martinelli P, Navarro D, Pedrero C, Mart\u00edn-Hijano L, et al. ISG15 and ISGylation is required for pancreatic cancer stem cell mitophagy and metabolic plasticity. Nat Commun. 2020;11:2682.","journal-title":"Nat Commun"},{"key":"3149_CR5","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1016\/j.canlet.2016.08.023","volume":"382","author":"Z Zhang","year":"2016","unstructured":"Zhang Z, Duan Q, Zhao H, Liu T, Wu H, Shen Q, et al. Gemcitabine treatment promotes pancreatic cancer stemness through the Nox\/ROS\/NF-\u03baB\/STAT3 signaling cascade. Cancer Lett. 2016;382:53\u201363.","journal-title":"Cancer Lett"},{"key":"3149_CR6","doi-asserted-by":"crossref","first-page":"3196","DOI":"10.7150\/thno.51976","volume":"11","author":"K Li","year":"2021","unstructured":"Li K, Zhang Z, Mei Y, Yang Q, Qiao S, Ni C, et al. Metallothionein-1G suppresses pancreatic cancer cell stemness by limiting activin A secretion via NF-\u03baB inhibition. Theranostics. 2021;11:3196\u2013212.","journal-title":"Theranostics"},{"key":"3149_CR7","doi-asserted-by":"crossref","first-page":"433","DOI":"10.1016\/j.stem.2011.10.001","volume":"9","author":"E Lonardo","year":"2011","unstructured":"Lonardo E, Hermann PC, Mueller MT, Huber S, Balic A, Miranda-Lorenzo I, et al. Nodal\/Activin signaling drives self-renewal and tumorigenicity of pancreatic cancer stem cells and provides a target for combined drug therapy. Cell Stem Cell. 2011;9:433\u201346.","journal-title":"Cell Stem Cell"},{"key":"3149_CR8","doi-asserted-by":"crossref","first-page":"1945","DOI":"10.1245\/s10434-010-0926-2","volume":"17","author":"KP Chang","year":"2010","unstructured":"Chang KP, Kao HK, Liang Y, Cheng MH, Chang YL, Liu SC, et al. Overexpression of activin A in oral squamous cell carcinoma: association with poor prognosis and tumor progression. Ann Surg Oncol. 2010;17:1945\u201356.","journal-title":"Ann Surg Oncol"},{"key":"3149_CR9","doi-asserted-by":"crossref","first-page":"1978","DOI":"10.1038\/bjc.2012.519","volume":"107","author":"MA Hoda","year":"2012","unstructured":"Hoda MA, M\u00fcnzker J, Ghanim B, Schelch K, Klikovits T, Laszlo V, et al. Suppression of activin A signals inhibits growth of malignant pleural mesothelioma cells. Br J Cancer. 2012;107:1978\u201386.","journal-title":"Br J Cancer"},{"key":"3149_CR10","doi-asserted-by":"crossref","DOI":"10.1038\/npjbcancer.2015.7","volume":"1","author":"M Bashir","year":"2015","unstructured":"Bashir M, Damineni S, Mukherjee G, Kondaiah P. Activin-A signaling promotes epithelial-mesenchymal transition, invasion, and metastatic growth of breast cancer. NPJ Breast Cancer. 2015;1:15007.","journal-title":"NPJ Breast Cancer"},{"key":"3149_CR11","first-page":"2644","volume":"42","author":"J Ge","year":"2019","unstructured":"Ge J, Sun H, Li J, Shan Y, Zhao Y, Liao F, et al. Involvement of CHOP in activin A-induced myeloma NS-1 cell apoptosis. Oncol Rep. 2019;42:2644\u201354.","journal-title":"Oncol Rep"},{"key":"3149_CR12","doi-asserted-by":"crossref","first-page":"245","DOI":"10.1080\/10799893.2020.1806316","volume":"41","author":"Y Hong","year":"2021","unstructured":"Hong Y, Gong L, Yu B, Dong Y. PPM1A suppresses the proliferation and invasiveness of RCC cells via Smad2\/3 signaling inhibition. J Recept Sig Transduct Res. 2021;41:245\u201354.","journal-title":"J Recept Sig Transduct Res"},{"key":"3149_CR13","doi-asserted-by":"crossref","first-page":"915","DOI":"10.1016\/j.cell.2006.03.044","volume":"125","author":"X Lin","year":"2006","unstructured":"Lin X, Duan X, Liang YY, Su Y, Wrighton KH, Long J, et al. PPM1A functions as a Smad phosphatase to terminate TGFbeta signaling. Cell. 2006;125:915\u201328.","journal-title":"Cell"},{"key":"3149_CR14","volume":"38","author":"F Zhu","year":"2018","unstructured":"Zhu F, Xie N, Jiang Z, Li G, Ma L, Tong T. The cellular senescence-inhibited gene is essential for PPM1A myristoylation to modulate transforming growth factor \u03b2 signaling. Mol Cell Biol. 2018;38:e00414-18.","journal-title":"Mol Cell Biol"},{"key":"3149_CR15","doi-asserted-by":"crossref","first-page":"741","DOI":"10.1042\/BJ20121201","volume":"449","author":"T Chida","year":"2013","unstructured":"Chida T, Ando M, Matsuki T, Masu Y, Nagaura Y, Takano-Yamamoto T, et al. N-Myristoylation is essential for protein phosphatases PPM1A and PPM1B to dephosphorylate their physiological substrates in cells. Biochem J. 2013;449:741\u20139.","journal-title":"Biochem J"},{"key":"3149_CR16","doi-asserted-by":"crossref","first-page":"6295","DOI":"10.2147\/OTT.S253082","volume":"13","author":"Y Liu","year":"2020","unstructured":"Liu Y, Fan X, Zhao Z, Shan X. LncRNA SLC7A11-AS1 contributes to lung cancer progression through facilitating TRAIP expression by inhibiting miR-4775. OncoTargets Ther. 2020;13:6295\u2013302.","journal-title":"OncoTargets Ther."},{"key":"3149_CR17","first-page":"6256","volume":"13","author":"L Yu","year":"2023","unstructured":"Yu L, Li J, Xiao M. LncRNA SLC7A11-AS1 stabilizes CTCF by inhibiting its UBE3A-mediated ubiquitination to promote melanoma metastasis. Am J Cancer Res. 2023;13:6256\u201369.","journal-title":"Am J Cancer Res"},{"key":"3149_CR18","doi-asserted-by":"crossref","first-page":"361","DOI":"10.4149\/neo_2023_230323N162","volume":"70","author":"FL Zeng","year":"2023","unstructured":"Zeng FL, Lin J, Xie X, Xie YK, Zhang JH, Xu D, et al. LncRNA SLC7A11-AS1 promotes the progression of hepatocellular carcinoma by mediating KLF9 ubiquitination. Neoplasma. 2023;70:361\u201374.","journal-title":"Neoplasma"},{"key":"3149_CR19","doi-asserted-by":"crossref","first-page":"974","DOI":"10.1016\/j.omtn.2019.11.035","volume":"19","author":"Q Yang","year":"2020","unstructured":"Yang Q, Li K, Huang X, Zhao C, Mei Y, Li X, et al. lncRNA SLC7A11-AS1 promotes chemoresistance by blocking SCF\u03b2-TRCP-mediated degradation of NRF2 in pancreatic cancer. Mol Ther Nucleic Acids. 2020;19:974\u201385.","journal-title":"Mol Ther Nucleic Acids"},{"key":"3149_CR20","volume":"8","author":"Y Gao","year":"2017","unstructured":"Gao Y, Zhang Z, Li K, Gong L, Yang Q, Huang X, et al. Linc-DYNC2H1-4 promotes EMT and CSC phenotypes by acting as a sponge of miR-145 in pancreatic cancer cells. Cell Death Dis. 2017;8:e2924.","journal-title":"Cell Death Dis"},{"key":"3149_CR21","volume":"93","author":"C Yang","year":"2019","unstructured":"Yang C, Liu X, Cheng T, Xiao R, Gao Q, Ming F, et al. LYAR suppresses beta interferon induction by targeting phosphorylated interferon regulatory factor 3. J Virol. 2019;93:e00769-19.","journal-title":"J Virol"},{"key":"3149_CR22","doi-asserted-by":"crossref","DOI":"10.1038\/s41598-021-87213-y","volume":"11","author":"G Mancinelli","year":"2021","unstructured":"Mancinelli G, Torres C, Krett N, Bauer J, Castellanos K, McKinney R, et al. Role of stromal activin A in human pancreatic cancer and metastasis in mice. Sci Rep. 2021;11:7986.","journal-title":"Sci Rep"},{"key":"3149_CR23","doi-asserted-by":"crossref","first-page":"1083","DOI":"10.1002\/jcsm.12461","volume":"10","author":"X Zhong","year":"2019","unstructured":"Zhong X, Pons M, Poirier C, Jiang Y, Liu J, Sandusky GE, et al. The systemic activin response to pancreatic cancer: implications for effective cancer cachexia therapy. J Cachexia Sarcopenia Muscle. 2019;10:1083\u2013101.","journal-title":"J Cachexia Sarcopenia Muscle"},{"key":"3149_CR24","doi-asserted-by":"crossref","first-page":"819","DOI":"10.1016\/j.canlet.2014.10.037","volume":"356","author":"Y Togashi","year":"2015","unstructured":"Togashi Y, Kogita A, Sakamoto H, Hayashi H, Terashima M, de Velasco MA, et al. Activin signal promotes cancer progression and is involved in cachexia in a subset of pancreatic cancer. Cancer Lett. 2015;356:819\u201327.","journal-title":"Cancer Lett"},{"key":"3149_CR25","doi-asserted-by":"crossref","first-page":"653","DOI":"10.3389\/fcell.2020.00653","volume":"8","author":"J Yang","year":"2020","unstructured":"Yang J, Jiang W. The role of SMAD2\/3 in human embryonic stem cells. Front Cell Dev Biol. 2020;8:653.","journal-title":"Front Cell Dev Biol"},{"key":"3149_CR26","doi-asserted-by":"crossref","first-page":"744","DOI":"10.1124\/mol.65.3.744","volume":"65","author":"S DaCosta Byfield","year":"2004","unstructured":"DaCosta Byfield S, Major C, Laping NJ, Roberts AB. SB-505124 is a selective inhibitor of transforming growth factor-beta type I receptors ALK4, ALK5, and ALK7. Mol Pharmacol. 2004;65:744\u201352.","journal-title":"Mol Pharmacol"},{"key":"3149_CR27","doi-asserted-by":"crossref","first-page":"1688","DOI":"10.1021\/acscentsci.8b00668","volume":"4","author":"P Skrinjar","year":"2018","unstructured":"Skrinjar P, Schwarz M, Lexm\u00fcller S, Mechtler TP, Zeyda M, Greber-Platzer S, et al. Rapid and modular assembly of click substrates to assay enzyme activity in the newborn screening of lysosomal storage disorders. ACS Cent Sci. 2018;4:1688\u201396.","journal-title":"ACS Cent Sci"},{"key":"3149_CR28","doi-asserted-by":"crossref","first-page":"18422","DOI":"10.1074\/jbc.M117.798827","volume":"292","author":"S Kim","year":"2017","unstructured":"Kim S, Yang X, Li Q, Wu M, Costyn L, Beharry Z, et al. Myristoylation of SRC kinase mediates SRC-induced and high-fat diet-accelerated prostate tumor progression in mice. J Biol Chem. 2017;292:18422\u201333.","journal-title":"J Biol Chem"},{"key":"3149_CR29","doi-asserted-by":"crossref","first-page":"6950","DOI":"10.1158\/0008-5472.CAN-17-0981","volume":"77","author":"S Kim","year":"2017","unstructured":"Kim S, Alsaidan OA, Goodwin O, Li Q, Sulejmani E, Han Z, et al. Blocking myristoylation of SRC inhibits its kinase activity and suppresses prostate cancer progression. Cancer Res. 2017;77:6950\u201362.","journal-title":"Cancer Res"},{"key":"3149_CR30","doi-asserted-by":"crossref","first-page":"6290","DOI":"10.1128\/MCB.00142-08","volume":"28","author":"L Ma","year":"2008","unstructured":"Ma L, Chang N, Guo S, Li Q, Zhang Z, Wang W, et al. CSIG inhibits PTEN translation in replicative senescence. Mol Cell Biol. 2008;28:6290\u2013301.","journal-title":"Mol Cell Biol"},{"key":"3149_CR31","doi-asserted-by":"crossref","first-page":"1606","DOI":"10.1161\/CIRCULATIONAHA.109.872200","volume":"120","author":"Y Oshima","year":"2009","unstructured":"Oshima Y, Ouchi N, Shimano M, Pimentel DR, Papanicolaou KN, Panse KD, et al. Activin A and Follistatin-like 3 determine the susceptibility of heart to ischemic injury. Circulation. 2009;120:1606\u201315.","journal-title":"Circulation"},{"key":"3149_CR32","volume":"12","author":"X Huang","year":"2021","unstructured":"Huang X, Pan L, Zuo Z, Li M, Zeng L, Li R, et al. LINC00842 inactivates transcription co-regulator PGC-1\u03b1 to promote pancreatic cancer malignancy through metabolic remodelling. Nat Commun. 2021;12:3830.","journal-title":"Nat Commun"},{"key":"3149_CR33","doi-asserted-by":"crossref","first-page":"448","DOI":"10.1016\/j.ymthe.2021.06.006","volume":"30","author":"Y Jiang","year":"2022","unstructured":"Jiang Y, Guo H, Tong T, Xie F, Qin X, Wang X, et al. lncRNA lnc-POP1-1 upregulated by VN1R5 promotes cisplatin resistance in head and neck squamous cell carcinoma through interaction with MCM5. Mol Ther J Am Soc Gene Ther. 2022;30:448\u201367.","journal-title":"Mol Ther J Am Soc Gene Ther"},{"key":"3149_CR34","doi-asserted-by":"crossref","first-page":"485","DOI":"10.1038\/s42255-019-0053-8","volume":"1","author":"Y Sun","year":"2019","unstructured":"Sun Y, Cai M, Zhong J, Yang L, Xiao J, Jin F, et al. The long noncoding RNA lnc-ob1 facilitates bone formation by upregulating Osterix in osteoblasts. Nat Metab. 2019;1:485\u201396.","journal-title":"Nat Metab"},{"key":"3149_CR35","volume":"18","author":"B Xiu","year":"2019","unstructured":"Xiu B, Chi Y, Liu L, Chi W, Zhang Q, Chen J, et al. LINC02273 drives breast cancer metastasis by epigenetically increasing AGR2 transcription. Mol Cancer. 2019;18:187.","journal-title":"Mol Cancer"},{"key":"3149_CR36","doi-asserted-by":"crossref","first-page":"920","DOI":"10.1016\/j.ymthe.2021.01.002","volume":"29","author":"M Abdel Mouti","year":"2021","unstructured":"Abdel Mouti M, Pauklin S. TGFB1\/INHBA Homodimer\/Nodal-SMAD2\/3 signaling network: a pivotal molecular target in PDAC treatment. Mol Ther J Am Soc Gene Ther. 2021;29:920\u201336.","journal-title":"Mol Ther J Am Soc Gene Ther"},{"key":"3149_CR37","doi-asserted-by":"crossref","first-page":"3053","DOI":"10.7150\/thno.19542","volume":"7","author":"J Zhuang","year":"2017","unstructured":"Zhuang J, Shen L, Yang L, Huang X, Lu Q, Cui Y, et al. TGF\u03b21 promotes gemcitabine resistance through regulating the LncRNA-LET\/NF90\/miR-145 signaling axis in bladder cancer. Theranostics. 2017;7:3053\u201367.","journal-title":"Theranostics"},{"key":"3149_CR38","volume":"8","author":"D Feng","year":"2022","unstructured":"Feng D, Zhou J, Liu H, Wu X, Li F, Zhao J, et al. Astrocytic NDRG2-PPM1A interaction exacerbates blood-brain barrier disruption after subarachnoid hemorrhage. Sci Adv. 2022;8:eabq2423.","journal-title":"Sci Adv"},{"key":"3149_CR39","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1016\/j.humpath.2017.05.021","volume":"66","author":"RF Coates","year":"2017","unstructured":"Coates RF, Gardner JA, Gao Y, Cortright VM, Mitchell JM, Ashikaga T, et al. Significance of positive and inhibitory regulators in the TGF-\u03b2 signaling pathway in colorectal cancers. Hum Pathol. 2017;66:34\u20139.","journal-title":"Hum Pathol"},{"key":"3149_CR40","volume":"12","author":"PC Xu","year":"2022","unstructured":"Xu PC, You M, Yu SY, Luan Y, Eldani M, Caffrey TC, et al. Visceral adipose tissue remodeling in pancreatic ductal adenocarcinoma cachexia: the role of activin A signaling. Sci Rep. 2022;12:1659.","journal-title":"Sci Rep"},{"key":"3149_CR41","doi-asserted-by":"crossref","first-page":"3586","DOI":"10.1210\/en.2006-0089","volume":"147","author":"Y Sidis","year":"2006","unstructured":"Sidis Y, Mukherjee A, Keutmann H, Delbaere A, Sadatsuki M, Schneyer A. Biological activity of follistatin isoforms and follistatin-like-3 is dependent on differential cell surface binding and specificity for activin, myostatin, and bone morphogenetic proteins. Endocrinology. 2006;147:3586\u201397.","journal-title":"Endocrinology"},{"key":"3149_CR42","doi-asserted-by":"crossref","first-page":"171","DOI":"10.1095\/biolreprod.111.098442","volume":"86","author":"TP Sharma","year":"2012","unstructured":"Sharma TP, Nett TM, Karsch FJ, Phillips DJ, Lee JS, Herkimer C, et al. Neuroendocrine control of FSH secretion: IV. hypothalamic control of pituitary FSH-regulatory proteins and their relationship to changes in FSH synthesis and secretion. Biol Reprod. 2012;86:171.","journal-title":"Biol Reprod"},{"key":"3149_CR43","doi-asserted-by":"crossref","first-page":"366","DOI":"10.1021\/acs.bioconjchem.8b00761","volume":"30","author":"S Benizri","year":"2019","unstructured":"Benizri S, Gissot A, Martin A, Vialet B, Grinstaff MW, Barth\u00e9l\u00e9my P. Bioconjugated oligonucleotides: recent developments and therapeutic applications. Bioconjug Chem. 2019;30:366\u201383.","journal-title":"Bioconjug Chem"}],"container-title":["British Journal of Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41416-025-03149-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41416-025-03149-4","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41416-025-03149-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,11,11]],"date-time":"2025-11-11T18:12:56Z","timestamp":1762884776000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41416-025-03149-4"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,9,9]]},"references-count":43,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2025,11,30]]}},"alternative-id":["3149"],"URL":"https:\/\/doi.org\/10.1038\/s41416-025-03149-4","relation":{},"ISSN":["0007-0920","1532-1827"],"issn-type":[{"value":"0007-0920","type":"print"},{"value":"1532-1827","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,9,9]]},"assertion":[{"value":"21 March 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"10 July 2025","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"1 August 2025","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"9 September 2025","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}},{"value":"All the animal procedures were approved by the Ethics Committee of the School of Life Science and Technology, Harbin Institute of Technology, and conducted in accordance with NIH guidelines for the Care and Use of Laboratory Animals.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}}]}}